ACRP blog

JANUARY 24, 2023

This expanded clinical research opportunities for patients as a core pillar of the affiliation’s mission, with the goal of providing access to novel treatments for diagnoses in addition to standard of care. An important step was a review of the state of clinical trial awareness at the time of the affiliation agreement.

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

Rethinking Clinical Trials

FEBRUARY 14, 2024

DCP developed an EHR-based workflows and integrated workflows within the local VA primary care setting. DCP developed 3 electronic workflows with 6 major configurations including applications needed outside of the EHR system. DCP developed a patient tracking tool that nurses could use to make sure patients got through each step.

Clinical Trials 152

Clinical Trials Clinical Trials Cardiology Trials 152

Drug Discovery World

OCTOBER 19, 2022

Following the news that the number of clinical trial recruiting sites in Ukraine has dropped by half since the Russian invasion, DDW’s Diana Spencer examines clinical trial data from analytics company Phesi and speaks to Dr Olena Karpenko , Clinical Research Director at Medical Center Ok!Clinic+

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

Velocity Clinical Research

NOVEMBER 21, 2023

“Without clinical research, there would be little if any development of new medicines,” says Isabelle Schenkenberger, MD. I’m proud and excited to be a part of it.” Dr. Schenkenberger is especially proud of her clinical trial research work in heart health, noting most new drugs never make it to market.

Medicine 59

Medicine Cardiology Clinical Research Clinical Trials 59

Velocity Clinical Research

JANUARY 3, 2024

The acquisition of KO-MED is Velocity’s first foray into Oncology research, which accounts for roughly 40-50% of clinical trials globally. KO-MED has been the leading multi-site network in Poland since 2020, having enrolled over 9,000 patients into clinical research.

Clinical Trials 52

Clinical Trials Clinical Trials Clinical Research Trials 52

The Pharma Data

OCTOBER 28, 2021

Bayer will present new renal and cardiovascular (CV) analyses from the comprehensive finerenone (Kerendia®) clinical trial program, including the Phase III FIGARO-DKD and FIDELIO-DKD studies, and the prespecified pooled analysis FIDELITY at the American Society of Nephrology (ASN)’s Kidney Week 2021 from 4-7 November.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Branding 52

The Pharma Data

SEPTEMBER 29, 2021

Heerspink, Professor of Clinical Trials and Personalized Medicine and a clinical pharmacologist/trialist at the Department of Clinical Pharmacy and Pharmacology at the University center Groningen, Netherlands, and Co-Chair of the study’s Executive Committee.

Clinical Development 52

Clinical Development Development Clinical Trials Clinical Trials 52

Scienmag

JUNE 17, 2021

Tools for clinicians in point-of-care use UTICA, NY — More than 2 million coronary artery stents are implanted each year to help protect or restore normal blood flow to the heart, to treat patients suffering from angina or a heart attack due to coronary artery disease (CAD). While stents are highly effective and safe devices, […].

Research 72

Research Development Clinical Trials Clinical Trials 72

pharmaphorum

OCTOBER 2, 2020

The five new NIHR National Patient Recruitment Centres (NPRCs) are set to shape the future of commercial clinical trials in the UK by offering new ways to conduct late-phase, large-scale research projects. The webinar will also cover: What the NPRCs’ franchise model means for research delivery.

Clinical Trials 92

Clinical Trials Clinical Trials Life Science Clinical Research 92

Scienmag

NOVEMBER 13, 2020

Empagliflozin, a recently developed diabetes drug, can effectively treat and reverse heart failure in both diabetic and non-diabetic patients, according to researchers at the Icahn School of Medicine at Mount Sinai.

Clinical Trials 61

Clinical Trials Clinical Trials Drugs Medicine 61

The Pharma Data

AUGUST 30, 2021

This is the finding of a study by investigators at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), published today in the Journal of the American College of Cardiology (JACC). The study is a prime example of collaboration between basic and clinical researchers.

Drugs 52

Drugs Cardiology Clinical Trials Clinical Trials 52

pharmaphorum

OCTOBER 2, 2020

The five new NHS Patient Recruitment Centres (NPRCs) are set to shape the future of commercial clinical trials in the UK by offering new ways to conduct late-phase, large-scale research projects. The webinar will also cover: What the NPRCs’ franchise model means for research delivery.

Clinical Trials 52

Clinical Trials Clinical Trials Life Science Clinical Research 52

Scienmag

JANUARY 11, 2021

COVID-19 pneumonia spreads like multiple wildfires, leaving destroyed lung tissue in its wake ‘This effort truly represents a “moonshot” in COVID-19 research’ Scientists identify target to treat COVID pneumonia and reduce severity Clinical trials with new experimental drug to begin early in 2021 Goal is to develop treatments (..)

Clinical Trials 49

Clinical Trials Clinical Trials Scientist Trials 49

XTalks

NOVEMBER 19, 2021

Cardiac biomarkers can not only serve important roles in the diagnosis, management and prognosis of cardiac diseases, but they can also be significant tools in evaluating treatments in cardiovascular (CV) clinical trials. In CV clinical trials, cardiac biomarkers are most commonly included in efficacy and safety endpoints.

Clinical Trials 98

Clinical Trials Clinical Trials Trials In-Vitro 98

The Pharma Data

FEBRUARY 21, 2022

At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business, which is aimed at delivering long-term, sustainable business growth by bringing forward new options for patients.

Radiology 52

Radiology Cardiology Development Production 52

pharmaphorum

JUNE 25, 2021

But Dr Craig Granowitz, chief scientific officer of cardiology drug developer Amarin, says that this is only the tip of the iceberg when it comes to the devastating impact of CVD on global populations. “In One of the key takeaways from COVID has been the importance of the endothelial cell – the lining of the blood vessel.

Cardiology 98

Cardiology Drugs Development Clinical Trials 98

Scienmag

MAY 16, 2021

A unique commission that today issued major new recommendations aimed at fully understanding and reducing the global burden of heart disease in women was led by Roxana Mehran, MD, Professor of Medicine, and Population Health Science and Policy, and Director of Interventional Cardiovascular Research and Clinical Trials at the Icahn School of Medicine (..)

Clinical Trials 50

Clinical Trials Clinical Trials Medicine Trials 50

The Pharma Data

JUNE 28, 2021

Bayer is proud of the approval of vericiguat in Japan and the contribution it has shown in clinical trials.”. Vericiguat is being jointly developed with MSD (a tradename of Merck & Co., The vericiguat program is being co-developed by Bayer and MSD. Kenilworth, NJ, USA). About Vericiguat Vericiguat 2.5

Cardiology 52

Cardiology Production Development Medicine 52

The Pharma Data

JANUARY 20, 2021

In order to do so, the DSMC may review unblinded study information (on a patient level or treatment group level) during the conduct of the trial. Dr. Rouleau has an international reputation in cardiovascular research, particularly in the field of both basic mechanisms and improving the clinical care of patients with heart failure.

Trials 52

Trials Cardiology Containment Development 52

Drug Discovery World

JULY 31, 2023

Based in France, CellProthera is a small, regenerative cell therapy developer that specialises in cardiovascular diseases. To develop its therapy, CellProthera must first take blood from a patient and bring that through to manufacture. CellProthera’s regenerative medicine approach to heart failure isn’t a new idea.

Medicine 52

Medicine Clinical Trials Clinical Trials Manufacturing 52

The Pharma Data

AUGUST 22, 2021

Alexion is discontinuing CHAMPION-ALS, the global Phase III clinical trial of Ultomiris (ravulizumab) in adults with amyotrophic lateral sclerosis (ALS). The IDMC recommended that the trial be discontinued due to lack of efficacy. Data from the trial will be provided to inform ongoing research.

Trials 52

Trials Clinical Trials Clinical Trials Cardiology 52

Delveinsight

JULY 22, 2021

Joachim Fruebis, chief development officer of BlueRock, said that receiving fast track designation from the FDA is a crucial step, which will help them further progress clinical development of their DA01 cell therapy approach for Parkinson’s disease. Both use machine learning to draw this information from MRI scans.

Cardiology 98

Cardiology Development Engineer Clinical Trials 98

Scienmag

APRIL 27, 2021

Researchers from Belgium, the Netherlands, Russia, and Italy have developed a breakthrough method for quickly, accurately, and reliably diagnosing cardiac arrhythmias. The technology principles are published in JACC: Clinical […]. They called it Directed graph mapping (DGM).

Scientist 96

Scientist Development Research Clinical Trials 96

WCG Clinical

MAY 22, 2023

Despite the growing consensus around the need for diversity in clinical trials, the industry still has a long way to go. As one respondent said: “Appropriate representation of ethnic groups and sex are critical to the scientific validity of research findings, and their absence can lead to false conclusions.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Cardiology 52

The Pharma Data

SEPTEMBER 5, 2021

The approval by the European Commission was based on interim results from the Phase III clinical trial in children and adolescents with PNH that demonstrated the safety and efficacy of Ultomiris in these patients.

Clinical Trials 52

Clinical Trials Clinical Trials Cardiology Trials 52

XTalks

AUGUST 22, 2022

The Toronto-based company has recently announced positive results from an independent clinical trial which showed that their fluorescence imaging device MolecuLight i :X improved 12-week wound healing of diabetic foot ulcers by 204 percent. Amlani: MolecuLight Inc.

Bacteria 111

Bacteria Containment Sales Cardiology 111

The Pharma Data

DECEMBER 15, 2020

15, 2020 — High blood pressure can begin to take a toll on memory and thinking skills as early as middle age, new Brazilian research warns. TUESDAY, Dec.

Cardiology 52

Cardiology Clinical Trials Clinical Trials Medicine 52

The Pharma Data

NOVEMBER 4, 2020

Caelum”) is a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines.

Antibody 52

Antibody Containment Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 30, 2021

1 Patients can develop a wide range of symptoms, including liver disease and/or psychiatric or neurological symptoms, such as personality changes, tremors and difficulty walking, swallowing or talking. ALXN1840 is a potential new once-daily, oral medicine in development for the treatment of Wilson disease.

Trials 52

Trials Genetics Cardiology Medicine 52

The Pharma Data

JULY 12, 2021

Up to 40% of all patients with type 2 diabetes develop chronic kidney disease. The Phase III FIDELIO-DKD trial is the first large contemporary positive outcomes study in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) with a primary composite endpoint consisting exclusively of kidney-specific outcomes.

FDA Approval 52

FDA Approval Cardiology Medicine Trials 52

XTalks

APRIL 15, 2021

Late-stage clinical trial failures are largely to blame for the lack of effective treatment options for patients with HFpEF, and poor five-year survival rates make this an area of great unmet need. The reverse could also be true whereby the development of coronary artery disease may impact heart rate. HFrEF vs. HFpEF.

Development 98

Development Drugs Genome Genomics 98

The Pharma Data

AUGUST 30, 2021

Professor of Cardiology at the National and Kapodistrian University of Athens, Greece, and co-principal investigator of the FIDELIO-DKD and FIGARO-DKD Phase III clinical trials. Up to 40% of all patients with type 2 diabetes develop chronic kidney disease.

HR 52

HR Cardiology Clinical Trials Clinical Trials 52

The Pharma Data

MARCH 31, 2023

Global Head, Cardiovascular, Renal and Metabolism Development Unit, Novartis. FortiHFy includes trials across the spectrum of HF, such as PARADIGM-HF, PIONEER-HF, PANORAMA-HF, TRANSITION, PROVE-HF, PARAGON-HF and PARAMOUNT. Entresto contains the neprilysin inhibitor sacubitril and the angiotensin receptor blocker (ARB) valsartan 4,5.

Medicine 75

Medicine Trials Cardiology Production 75

Scienmag

MAY 16, 2021

In the first-ever global report on cardiovascular disease (CVD) in women, researchers call for urgent action to improve care and prevention, fill knowledge gaps, […].

Research 57

Research Clinical Trials Clinical Trials Cardiology 57

The Pharma Data

NOVEMBER 2, 2020

an international research-focused healthcare Group (Chiesi Group), received U.S. Bronchitol was developed by Pharmaxis Ltd., market and congratulate all Chiesi team members and partners who supported the clinical process.”. 02, 2020 (GLOBE NEWSWIRE) — Chiesi USA, Inc., affiliate of Chiesi Farmaceutici S.p.A.,

FDA Approval 52

FDA Approval Bacteria Medicine Cardiology 52

The Pharma Data

DECEMBER 8, 2020

The company’s commercial priorities are three-fold: (1) Initially focusing its commercial efforts on rare diseases within its prolific neurology and cardiology franchises (2) pioneer new markets where there are no available treatments (3) create new standards of care where there has been a lack of innovation to optimize patient care.

Medicine 52

Medicine RNA Production Marketing 52

The Pharma Data

MARCH 22, 2022

New data, including two late-breaking clinical trial presentations on mavacamten and a new analysis of the GUARD-AF study, reinforce the company’s continued commitment to those living with cardiovascular disease. senior vice president, head of cardiovascular development and global drug development at Bristol Myers Squibb.

Clinical Trials 52

Clinical Trials Clinical Trials Cardiology Trials 52